Try our mobile app
Screener

Reviews

2024-03-29
#reports #ENSV

[Enservco Corporation](https://eninvs.com/all.php?name=ENSV) (Oil and Gas Equipment and Services) reported for [2023 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=165051)
(2024-03-28, Before Market Open):

- Revenue -14.3% YoY (vs 0.0% in previous quarter and historical rate +27.5%)
- EBITDA margin -16.7% decreased compared to -14.3% same period last year
- Net Debt increased by $2.0 mln over the past reporting period (44.8% of market cap)
- FCF (LTM) +$0.0 bln (positive), 358.7% of market cap
- EV/Sales multiple is 0.5x

At the opening of the session the share price went up +1.9% vs S&P500 0.0%
2024-03-29
#reports #CMCT

[CIM Commercial Trust Corporation](https://eninvs.com/all.php?name=CMCT) (REIT — Office) reported for [2023 q4](https://eninvs.com/press_release.php?ticker=CMCT&q=2023 q4&id=763902)
(2024-03-27, After Market Close):

- Revenue +11.5% YoY (vs +12.0% in previous quarter and historical rate +17.3%)
- EBITDA +122.2% YoY (vs +1000.0% in previous quarter and historical rate +89.7%)
- EBITDA margin 69.0% increased compared to 34.6% same period last year
- EV/EBITDA multiple is 18.5x compared to historical level (75th percentile) of 58.4x
- EV/Sales multiple is 15.8x

At the opening of the session the share price went down -1.4% vs S&P500 0.0%
2024-03-29
#reports #WBA

[Walgreens Boots Alliance](https://eninvs.com/all.php?name=WBA) (Network of retail pharmacies) reported for [2024 q1](https://eninvs.com/press_release.php?source=sec&form_type=10&id=164970)
(2024-03-28, Before Market Open):

- Revenue +6.3% YoY (vs +11.0% in previous quarter and historical rate +1.7%)
- EBITDA -1758.8% YoY (vs -1254700.0% in previous quarter and historical rate -44.9%)
- EBITDA margin -33.9% decreased compared to 2.2% same period last year
- Net Debt increased by $1.7 bln over the past reporting period (9.1% of market cap)
- FCF (LTM) +$9.3 bln (positive), 49.7% of market cap
- EV/Sales multiple is 0.4x

The company showed EPS -$14.14 per share. At the opening of the session the share price went down -2.0% vs S&P500 0.0%
2024-03-29
#reports #STRS

[Stratus Properties](https://eninvs.com/all.php?name=STRS) (Real Estate — Diversified) reported for [2023 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=165013)
(2024-03-25, Before Market Open):

- Revenue -69.2% YoY (vs -60.0% in previous quarter and historical rate -8.6%)
- EBITDA margin -25.0% increased compared to -46.2% same period last year
- EV/Sales multiple is 22.3x

At the opening of the session the share price went up +1.6% vs S&P500 -0.3%
2024-03-29
#reports #SMTC

[Semtech](https://eninvs.com/all.php?name=SMTC) (Semiconductor manufacturer) reported for [2023 q4](https://eninvs.com/press_release.php?ticker=SMTC&q=2023 q4&id=763972)
(2024-03-28, After Market Close):

- Revenue +14.9% YoY (vs +12.9% in previous quarter and historical rate +14.1%)
- EBITDA margin -320.2% decreased compared to -24.4% same period last year
- Net Debt decreased by $7.0 mln over the past reporting period (0.4% of market cap)
- FCF (LTM) -$0.1 bln (negative), 7.8% of market cap
- EV/Sales multiple is 3.5x

The company showed EPS -$9.98 per share
2024-03-29
#reports #RKDA

[Arcadia Biosciences](https://eninvs.com/all.php?name=RKDA) (Agricultural Inputs) reported for [2023 q4](https://eninvs.com/press_release.php?ticker=RKDA&q=2023 q4&id=763971)
(2024-03-28, After Market Close):

- Revenue 0.0% YoY (vs 0.0% in previous quarter and historical rate +64.2%)
- EBITDA margin -300.0% increased compared to -600.0% same period last year
- Net Debt increased by $4.0 mln over the past reporting period (302.0% of market cap)
- FCF (LTM) -$0.0 bln (negative), 452.9% of market cap
- EV/EBITDA multiple is 0.7x compared to historical level (75th percentile) of 0.9x
- EV/Sales multiple is -1.6x

On post-market the stock shows a growth by +3.2%
2024-03-29
#reports #POAI

[Predictive Oncology](https://eninvs.com/all.php?name=POAI) (Medical Instruments and Supplies) reported for [2023 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=165044)
(2023-05-17, After Market Close):

- Revenue -7.7% YoY (vs +56.8% in previous quarter and historical rate +73.4%)
- EBITDA margin -991.3% increased compared to -2195.9% same period last year
- Net Debt increased by $3.0 bln over the past reporting period (1631.5% of market cap)
- FCF (LTM) -$13.8 bln (negative), 7423.3% of market cap
- EV/EBITDA multiple is 0.8x compared to historical level (75th percentile) of 1.5x
- EV/Sales multiple is -4.4x

2024-03-29
#reports #PMD

[Psychemedics Corporation](https://eninvs.com/all.php?name=PMD) (Diagnostics and Research) reported for [2023 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=165010)
(2024-03-25, After Market Close):

- Revenue -16.7% YoY (vs -14.3% in previous quarter and historical rate +9.1%)
- EBITDA margin -20.0% decreased compared to 16.7% same period last year
- EV/Sales multiple is 0.8x

At the opening of the session the share price went up +0.7% vs S&P500 +0.2%
2024-03-29
#reports #MTEX

[Mannatech](https://eninvs.com/all.php?name=MTEX) (Household and Personal Products) reported for [2023 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=165028)
(2024-03-25, Before Market Open):

- Revenue -2.9% YoY (vs -8.3% in previous quarter and historical rate +1.3%)
- EBITDA -20.0% YoY (vs 0.0% in previous quarter)
- EBITDA margin 12.1% decreased compared to 14.7% same period last year
- EV/EBITDA multiple is 2.0x compared to historical level (75th percentile) of 2.9x
- EV/Sales multiple is 0.1x

2024-03-29
#reports #GRNQ

[Greenpro Capital](https://eninvs.com/all.php?name=GRNQ) (Consulting Services) reported for [2023 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=165039)
(2022-05-10):

- Revenue 0.0% YoY (vs 0.0% in previous quarter and historical rate +50.0%)
- EBITDA margin -100.0% decreased compared to 0.0% same period last year
- Net Debt decreased by $2.0 mln over the past reporting period (18.9% of market cap)
- EV/Sales multiple is 2.1x

2024-03-29
#reports #FEMY

[Femasys Inc.](https://eninvs.com/all.php?name=FEMY) (Medical Instruments and Supplies) reported for [2023 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=164983)
(2024-03-28, Before Market Open):

- Revenue -11.1% YoY (vs -29.7% in previous quarter and historical rate +73.0%)
- EBITDA margin -1308.3% decreased compared to -270.8% same period last year
- Net Debt decreased by $9.2 bln over the past reporting period (50160.9% of market cap)
- FCF (LTM) +$2.6 bln (positive), 14182.7% of market cap
- EV/EBITDA multiple is 0.6x compared to historical level (75th percentile) of 1.4x
- EV/Sales multiple is -7.8x

At the opening of the session the share price went down -2.0% vs S&P500 0.0%
2024-03-29
#reports #FBIOP

[Fortress Biotech](https://eninvs.com/all.php?name=FBIOP) (Biotechnology) reported for [2023 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=165042):

- Revenue +25.0% YoY (vs +105.9% in previous quarter and historical rate +33.8%)
- EBITDA margin -500.0% has not changed compared to -500.0% same period last year
- Net Debt increased by $11.0 mln over the past reporting period (8.8% of market cap)
- FCF (LTM) -$0.0 bln (negative), 16.1% of market cap
- EV/Sales multiple is 1.3x

2024-03-29
#reports #CURV

[Torrid Holdings Inc.](https://eninvs.com/all.php?name=CURV) (Apparel Retail) reported for [2023 q4](https://eninvs.com/press_release.php?ticker=CURV&q=2023 q4&id=763965)
(2024-03-28, After Market Close):

- Revenue -2.3% YoY (vs -5.2% in previous quarter and historical rate -7.5%)
- EBITDA +16.7% YoY (vs -44.8% in previous quarter and historical rate -29.4%)
- EBITDA margin 4.8% increased compared to 4.0% same period last year
- Net Debt decreased by $3.0 mln over the past reporting period (0.6% of market cap)
- FCF (LTM) +$0.0 bln (positive), 6.7% of market cap
- EV/EBITDA multiple is 10.5x compared to historical level (75th percentile) of 9.6x
- EV/Sales multiple is 0.9x

2024-03-29
#dividend #BKE

The Buckle will pay dividends in the amount of 0.35 USD per share on 2024-04-10, which is 0.9% of the current price 40.27. Together with previous payments, the annual dividend yield will be 9.7%

(2024-01-10: 2.85 USD)
(2023-10-11: 0.35 USD)
(2023-07-12: 0.35 USD)
2024-03-29
#dividend #CMCT

CIM Commercial Trust Corporation will pay dividends in the amount of 0.085 USD per share on 2024-04-04, which is 2.0% of the current price 4.26. Together with previous payments, the annual dividend yield will be 8.0%

(2023-10-04: 0.17 USD)
(2023-07-06: 0.085 USD)
2024-03-29
#dividend #EC

Ecopetrol will pay dividends in the amount of 0.7999 USD per share on 2024-04-03, which is 6.8% of the current price 11.84. Together with previous payments, the annual dividend yield will be 20.7%

(2023-12-18: 0.828 USD)
(2023-09-25: 0.8276 USD)
2024-03-28
#reports #WBA

[Walgreens Boots Alliance](https://eninvs.com/all.php?name=WBA) (Network of retail pharmacies) reported for [2023 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=161129)
(2024-01-04, Before Market Open):

- Revenue +11.0% YoY (vs +9.2% in previous quarter and historical rate +0.5%)
- EBITDA margin -33.9% decreased compared to -16.9% same period last year
- Net Debt increased by $166.0 mln over the past reporting period (0.9% of market cap)
- FCF (LTM) -$1.5 bln (negative), 8.4% of market cap
- EV/Sales multiple is 0.4x

The company showed EPS -$0.08 per share vs analyst consensus of +$0.95. At the opening of the session the share price went down -5.4% vs S&P500 -0.2%
2024-03-28
#reports #JFIN

[Jiayin Group](https://eninvs.com/all.php?name=JFIN) (Internet Content and Information) reported for 2023 q4
(2024-03-28, Before Market Open):

- Revenue +47.1% YoY (vs +59.5% in previous quarter and historical rate +67.1%)
- EBITDA -22.9% YoY (vs +10.4% in previous quarter and historical rate +88.0%)
- EBITDA margin 24.0% decreased compared to 45.8% same period last year
- EV/EBITDA multiple is 1.3x compared to historical level (75th percentile) of 1.4x
- EV/Sales multiple is 0.4x

At the opening of the session the share price went down -3.9% vs S&P500 0.0%
2024-03-28
#reports #DRIO

[DarioHealth](https://eninvs.com/all.php?name=DRIO) (Diagnostics and Research) reported for [2023 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=164962)
(2024-03-28, Before Market Open):

- Revenue -42.9% YoY (vs -42.9% in previous quarter and historical rate +49.3%)
- EBITDA +55.6% YoY (vs +6.7% in previous quarter and historical rate +88.5%)
- EBITDA margin 350.0% increased compared to 128.6% same period last year
- Net Debt decreased by $26.0 mln over the past reporting period (74.8% of market cap)
- FCF (LTM) -$0.0 bln (negative), 74.8% of market cap
- EV/Sales multiple is -0.7x

At the opening of the session the share price went up +1.3% vs S&P500 0.0%
2024-03-28
#reports #CAAS

[China Automotive Systems](https://eninvs.com/all.php?name=CAAS) (Auto Parts) reported for [2023 q4](https://eninvs.com/press_release.php?source=sec&form_type=10&id=164963)
(2024-03-28, Before Market Open):

- Revenue +23.3% YoY (vs +0.7% in previous quarter and historical rate +31.8%)
- EBITDA +280.0% YoY (vs +40.0% in previous quarter and historical rate +80.2%)
- EBITDA margin 11.9% increased compared to 3.9% same period last year
- Net Debt decreased by $47.0 mln over the past reporting period (46.2% of market cap)
- FCF (LTM) -$0.0 bln (negative), 37.4% of market cap
- EV/Sales multiple is -0.0x

At the opening of the session the share price went up +5.9% vs S&P500 0.0%
2024-03-28
#reports #VRNT

[Verint Systems](https://eninvs.com/all.php?name=VRNT) (Software developer) reported for 2023 q4
(2024-03-27, After Market Close):

- Revenue +12.3% YoY (vs -2.7% in previous quarter and historical rate -9.0%)
- EBITDA -14.3% YoY (vs +105.1% in previous quarter and historical rate -27.5%)
- EBITDA margin 15.8% decreased compared to 20.8% same period last year
- Net Debt decreased by $671.0 mln over the past reporting period (34.4% of market cap)
- FCF (LTM) +$0.9 bln (positive), 45.0% of market cap
- EV/EBITDA multiple is 20.6x compared to historical level (75th percentile) of 28.9x
- EV/Sales multiple is 2.9x